EyePoint Pharmaceuticals (STU:PV3) Beginning Cash Position : €258.90 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Beginning Cash Position?

EyePoint Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2024 was €258.90 Mil.

EyePoint Pharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2023 (€130.94 Mil) to Dec. 2023 (€122.13 Mil) but then increased from Dec. 2023 (€122.13 Mil) to Mar. 2024 (€258.90 Mil).

EyePoint Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2021 (€39.88 Mil) to Dec. 2022 (€168.73 Mil) but then declined from Dec. 2022 (€168.73 Mil) to Dec. 2023 (€87.83 Mil).

EyePoint Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for EyePoint Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Beginning Cash Position Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

40.87

18.38

39.88

168.73

87.83

EyePoint Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															89.46	97.76	130.94	122.13	258.90

EyePoint Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

EyePoint Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3) Headlines

No Headlines